Allele Burden and MPNs Explained by Prof. Lucia Masarova

Published on February 10, 2025

At the 4th MPN Spring Symposium in Barcelona, Prof. Lucia Masarova, Assistant Professor at The University of Texas MD Anderson Cancer Center, discussed the concept of allele burden and its role in managing Myeloproliferative Neoplasms (MPNs). 

 

 

 

 

 

 

 

 

 

 

 

She explained how the percentage of cells with a specific mutation can impact disease progression, guide treatment decisions, and predict patient outcomes, especially for polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF).

 

LINK

 

Other news

What are MPNs?

February 5, 2025
Do you know what MPN stands for? If not, you are not alone.  MPN stands for myeloproliferative neoplasm, a group of blood cancers that cause an overproduction of one or more types of blood cells. If you or a loved one has been diagnosed with a myeloproliferative neoplasm (MPN), you might wonder what it is and how it affects your health. MPNs are a group of rare blood cancers that occur when the bo

MPN Hope Series: Vanesa’s Testimony

February 25, 2025
At the Global MPN Scientific Foundation, we are committed to amplifying the voices of those living with Myeloproliferative Neoplasms (MPNs). As part of our MPN Hope series, we are honored to share the inspiring testimony of Vanesa, a patient diagnosed with Primary Myelofibrosis (MF).         Vanesa’s Journey: A Story of Adaptation and StrengthVanesa first learned about her condition during a routi